数字平台优化指南导向的心力衰竭治疗:AIM-POWER试验结果
Adam D DeVore1, Maulik Majmudar2, Leigh Etters2
1Duke Clinical Research Institute and Department of Medicine, Duke University School of Medicine, Durham, NC (A.D.D., A.F.H.).
Circulation. Heart failure
|December 3, 2025
概括
数字干预显著改善了心力衰竭 (HF) 患者的指导方针推的医疗治疗. 这种远程定位程序与常规护理相比,提高了HF最佳治疗得分.
科学领域:
- 心脏病学 心脏病学
- 数字健康数字健康
- 临床试验 临床试验
背景情况:
- 在美国心力衰竭 (HF) 患者中,指导方针推的药物治疗未得到充分利用,其排气分数减少 (HFrEF).
- 远程定位程序提供了一个潜在的解决方案,以提高对指导方针导向医疗治疗的坚持.
研究的目的:
- 评估数字干预措施的安全性和有效性,以优化HFrEF患者的药理疗法.
- 评估远程数据收集和临床医生建议对药物定位的影响.
主要方法:
- 该AIM-POWER试验是一项多中心的开放性研究,涉及HFrEF的参与者,这些参与者在医疗治疗中没有优化.
- 参与者被随机分配到数字干预 (BiovitalsHF) 或常规护理,数据远程收集90天.
- 主要结局是HF最佳治疗得分的变化.
主要成果:
- 122名参与者被随机分配到21个美国地点.
- 与通常护理组相比,干预组的HF最佳治疗得分显著增加 (1.72比0.44,P<0.001).
- 平均年龄为61.6±12.4岁,69%是男性,平均射出分数为29±6.7%.
结论:
- 一项以药理疗法优化为重点的数字干预措施显著改善了HFrEF患者的HF最佳治疗得分.
- 这种数字方法在加强心力衰竭管理指南推的护理方面表现出有效性.
相关概念视频
Heart Failure V: Medical Management
200
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
200
Heart Failure VI: Adjunct Therapies
235
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
235
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
888
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
888
Heart Failure IV: Classification and Diagnostic Evaluation
295
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
295
Cardiomyopathy V: Interprofessional Care
314
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
314
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K


